Senate adopts user fee bill in rare 'Kumbaya' moment
This article was originally published in Scrip
Executive Summary
In what Senate Majority Leader Harry Reid (Democrat-Nevada) declared a “good day in Washington,” the US Senate on 24 May came together in a rare bipartisan move to adopt the legislative package aimed at ensuring the US FDA can continue to collect user fees from drug and device makers, with new fees from generic and biosimilar manufacturers.
You may also be interested in...
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Sen. Burr asks FDA whether fee revenue should be rebated for not meeting some PDUFA V goals.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.